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Summary
We have reported the identification of human gene MAGE-1, which directs the expression of
an antigen recognized on a melanoma by autologous cytolytic T lymphocytes (CTL). We show
here that CTL directed against this antigen, which was named MZ2-E, recognize a nonapeptide
encoded by the third exon of gene MAGE-1 . The CTL also recognize this peptide when it is
presented by mouse cells transfected with an HLA-A1 gene, confirming the association ofantigen
MZ2-E with the HLAA1 molecule. Other members of the MAGE gene family do not code
for the same peptide, suggesting that only MAGE-1 produces the antigen recognized by the
anti-MZ2-E CTL. Our results open the possibility of immunizing HLAA1 patients whose tumor
expresses MAGE-1 either with the antigenic peptide or with autologous antigen-presenting cells
pulsed with the peptide .
ixed lymphocyte-tumor cell cultures carried out with
human melanoma cells and lymphocytes of the same
patient often generate CTL that lyse the autologous tumor
cells (1-4) . Using blood lymphocytes of melanoma patient
MZ2, we have obtained a panel of CD8+ CTL clones that
lyse the autologous tumor cell line MZ2-MEL (3) . Antigen-
loss variants of MZ2-MEL were obtained by selecting tumor
cells that were resistant to some of these CTL clones . The
pattern of resistance of these antigen-loss variants demon-
strated that six different antigens are recognized on the tumor
cells by the autologous CTL (5) . To identify the gene of one
of these antigens, which was named MZ2-E (E), a cosmid
library prepared with the DNA of a MZ2-MEL subclone was
transfected into E - antigen-loss variant MZ2-MEL.2.2 . This
led to the isolation of gene MAGE-1, which directs the ex-
pression of antigen MZ2-E (6, 7) . The gene was found to
be deleted in the antigen-loss variant .
Gene MAGE-1 comprises three exons. A large open reading
frame is entirely contained in the third exon. The sequence
of the gene found in normal cells of the patient appears to
be identical to that found in the melanoma cells . The gene
does not appear to be expressed in normal tissues, but it is
expressed in -40% of the melanoma cell lines and tumor
samples that have been analyzed (8) .
Gene MAGE-1 belongs to a family of several closely re-
lated genes . Melanoma MZ2-MEL expresses, in addition to
MAGE-1, two other members of this family, called MAGE-2
and MAGE-3. These two genes do not direct the expression
of antigen MZ2-E. Like MAGE-1, they do not appear to be
expressed in normal tissues.
There is now overwhelming evidence that CD8+ CTL
recognize their antigen in the form of a small peptide bound
to a class I MHC molecule (9-11) . This implies that each
MAGE gene expressed in tumor cells could provide one or
more peptides binding to some class I molecule, thus providing
a tumor-specific antigen . As a first step in the analysis ofthese
potential antigens, we report here the identification of a
MAGE-1-encoded nonapeptide that combines with HLA-A1
to form antigen MZ2-E.
Materials and Methods
Cell Lines.
	
Melanoma cell line MZ2-MEL was derived from
patient MZ2, and a number of subclones were obtained (3) . Clonal
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subline MZ2-MEL.2 .2 was selected from subclone MZ2-MEL.3 .1
with an autologous CTLclone (5). Anti-MZ2-E autologous CTL
clone 82/30 and its culture conditions have been described else-
where (6) . Mouse cell line PLHTR was derived from mastocy-
toma P815 (12) . P1.HTR was cotransfected with an HLA-A1 gene
(13), inserted in expression vector pcD-SRa (14), and with
pSVtkneoO (15) . The neon transfectants were cloned and tested for
HLA class I expression by flow cytometry using F(ab')2 fragments
of mAb B.9.12.1 (16) . One of these clones expressing HLA class
I was then cotransfected with a MAGE-1 cDNA, inserted in
expression vector pcD-SRa, and with pHMR272 (17) . The
hygromycin-resistant transfectants were cloned and tested for the
expression ofantigen MZ2-Eon the basis of their ability to stimu-
late the production of TNF by CTL 82/30 (6).
Cloning ofSubgenic Fragments of Gene MAGE-1 .
	
The 2.4-kb
BamHI fragment containing exons 2 and 3 of gene MAGE-1 and
smaller parts of this fragment were cloned in plasmid vector pTZ18R
(Pharmacia Fine Chemicals, Piscataway, NJ). Expression vector
pSVK3 (Pharmacia Fine Chemicals) was used to clone a 300-bp
fragment, obtained by PCRamplification ofMAGE-1 with oligo-
nucleotides VDB14 (5'-CAGGGAGCCAGTCACAAAG-3') and
CH09 (5'-ACTCAGCTCCTCCCAGATTT3') (positions 422-722
in the third exon).
Transfection of MAGE-1 Fragments and Screening of the Transfec-
tants . Transfections were performed by the calcium phosphate
precipitation method (6, 18). Briefly, 4 x 106 cells were treated
with 3 Ag of pSVtkneoO (15) as selective marker and 30 pg of
pTZ18R or pSVK3 containing a MAGE-1 insert . The neo' trans-
fectants were selected in medium containing 2 mg/ml ofneomycin
analogue G418 (Gibco Laboratories, Grand Island, NY). 15 d after
transfection, the geneticin-resistant transfectants were tested for
their ability to stimulate the production of TNF by anti-E CTL
82/30 (6). Briefly, 100 jA1 containing 1,500 CTL 82/30 was added
to 4 x 10 4 transfected cells in flat-bottomed microwells . After
24 h, 50 F,1 of the supernatant was harvested and added to 3 x 104
cells of WEHI 164 clone 13 (19) to evaluate the presence of TNF.
The mortality of WEHI cells was estimated 24 h later in a MTT
colorimetric assay (6, 20).
Antigenic Peptides and CTL Assay. Peptides were synthesized
on solid phase using F-moc for transient NH2-terminal protection
as described by Atherton et al . (21), purified by C-18 reverse-phase
HPLC, and characterized by amino acid analysis. Lysis of target
cells by CTL was tested by chromium release as previously described
(22) . In the peptide sensitization assay, 1,000 "Cr-labeled E -
target cells were incubated in 96-well microplates in the presence
ofvarious concentrations of peptide for 30 min at 37°C . An equal
volume containing the CTL was then added. Chromium release
was measured after 4 h at 37°C . We have indicated in Figs . 2 and
3 the final concentration of peptides during the incubation of the
target cells with the CTL.
Results
Identification ofthe MAGE-1 Region Codingfor the Antigenic
Peptide. We reported previously, that a 2.4-kb BamHlfrag-
ment containing only exons 2 and 3 of gene MAGE-1 transfers
at high efficiency the expression of antigen MZ2-E when it
is transfected into E- antigen-loss variant MZ2-MEL.2.2
(7) . This confirmed our previous experience with several genes
coding for antigens recognized by CTL on mouse tumors :
the transfection of small gene fragments that contain the se-
quence coding for an antigenic peptide results regularly in
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Figure 1 . Fragments of gene MAGE-1 that transfer the expression of
antigen MZ2-E. The gene is represented with exons as black boxes and
the open reading frame of exon 3 as a white box. The restriction frag-
ments were cloned in pTZ18R . The 300-bp fragment obtained by PCR
amplification with oligonucleotides VDB14 and CH09 was cloned in ex-
pression vector pSVK3. Each construct was cotransfected into MZ2-
MEL.2 .2 (E -) cells with pSVtkneoO as selective marker. The neo, popu-
lations expressing antigen MZ2-E were identified by their ability to stimulate
anti-E MZ2-CTL clone 82/30 to produce TNF. For the DNAfragments
marked +, the CTL stimulated with the transfectants produced superna-
tants causing the lysis of 17-93% of the WEHI test cells in the conditions
described in Materials and Methods (this corresponds to 12.5-100 pg/ml
rhuTNF-R). With the fragments marked -, <4% lysis was observed (cor-
responding to <1 .3 pg/ml rhuTNF-f3) . When control E' and E - MZ2-
MEL cells were tested in the same conditions as the transfectants, they
produced CTL supernatants lysing, respectively, 78 and 2% of the WEHI
cells (corresponding to 46 and 1.1 pg/ml rhuTNF-/3) .
the expression of the antigen, even when these fragments
are cloned in vectors that are not expression vectors (23, 24).
Accordingly, we cloned smaller MAGE-1 fragments obtained
with restriction enzymes or by PCR amplification, as indi-
cated in Fig. 1. These fragments were cotransfected with
Peptide concentration (nM)
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Figure 2. Lysis by anti-MZ2-E CTL of cells incubated with MAGE-1-
derived peptides . 51Cr-labeled MZ2-MEL.2 .2 (E -) cells were incubated
with CTL 82/30 at an E/T ratio of 5:1, in the presence of the synthetic
peptides shown on the right at the concentrations indicated. Chromium
release was measured after 4 h. The arrows indicate the level of lysis of
E' and E- MZ2-MEL cells incubated without peptides .
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pSVtkneoo into the E- line, and the geneticin-resistant
population was tested for its ability to stimulate TNF release
by autologous anti-E CTL clone 82/30 (6) . Thus, we identified
a 300-bp fragment of exon 3 that was capable of transferring
efficiently the expression of antigen MZ2-E. In agreement
with the results obtained with several mouse genes (23, 25-27),
this fragment was located in the large open reading frame
of gene MAGE-1 (Fig . 1) .
The Antigenic Peptide.
	
In the search for potential peptide
sequences, we focused on those parts of the 300-bp fragment
where the MAGE-1 amino acid sequence differs from that
of MAGE-2 and -3 . This was based on the observation that
genes MAGE-2 and -3 do not direct the expression of an-
tigen MZ2-E. Several 15-amino acid peptides were synthe-
sized . Sensitization of E- cells to lysis by the anti-E CTL
was observed with a peptide that corresponds to codons
158-172 of the large open reading frame ofMAGE-1. Shorter
peptides were prepared, and efficient lysis of E- cells was ob-
served with nonapeptide EADPTGHSY (codons 161-169)
(Figs . 2 and 3) . Half-maximal lysis was obtained at a peptide
concentration of 5 nM (Fig . 2) . In agreement with the evi-
dence that most peptides recovered from MHC class I mole-
cules are nonapeptides (11), we found that the removal of
either the NH2-terminal Glu or the COOH-terminal Tyr
abolished the ability of the peptide to sensitize cells to lysis
(Fig. 2) .
Presentation ofthe Peptide L . HLAA1. Previous experiments
involving the transfection of gene MAGE-1 into tumor cells
of various haplotypes suggested that HLAA1 was the pre-
senting molecule of antigen MZ2-E (7) . To definitively prove
this point, we transfected an HLA-A1 gene (13) into P1.HTR,
a highly transfectable variant derived from mouse tumor cell
line P815. When these P1.HTR.A1 cells were incubated in
the presence of the MZ2-E nonapeptide, they were lysed by
the anti-MZ2-E CTL (Fig. 3), as were P1.HTR.A1 cells trans-
fected with a MAGE-1 cDNA, indicating that the MZ2-E
peptide can be produced and transported in these mouse cells
(Fig. 3) .
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MAGE 1 GAA GCA GAC CCC ACC GGC CAC TCC TAT
MAGE 2 GAA GTG GTC CCC ATC AGC CAC TTG TAC
MAGE 21 GAA GTG GTC CGC ATC GGC CAC TTG TAC
MAGE 3 GAA GTG GAC CCC ATC GGC CAC TTG TAC
MAGE 4 GAA GTG GAC CCC GCC AGC AAC ACC TAC
MAGE 41 GAA GTG GAC CCC ACC AGC AAC ACC TAC
MAGE 5 GAA GCG GAC CCC ACC AGC AAC ACC TAC
MAGE 51 GAA GCG GAC CCC ACC AGC AAC ACC TAC
MAGE 6 GAA GTG GAC CCC ATC GGC CAC GTG TAC
Figure 4 . Comparison of peptide MZ2-E encoded by gene MAGE-1
with the peptides encoded by the homologous regions of other genes of
the MAGE family. These MAGE genes were isolated from cosmid libraries
prepared with genomic DNA isolated from a MZ2-MEL melanoma cell
line or from blood lymphocytes of patient MZ2 .
Discussion
To our best knowledge, only one other HLA-A1 bind-
ing peptide has been identified so far. This is a 13-amino
acid peptide corresponding to residues 89-101 of the influenza
A nucleoprotein (28) . The sequence of this peptide (PKK-
TGGPIYKRVD) shows no obvious similarity with the MZ2-E
peptide, except possibly for the Gly and Tyr residues at posi-
tions 6 and 9 of the MZ2-E peptide . The COOH-terminal
Tyr may serve as anchoring residue, as reported for Kd- and
Kb-restricted antigenic peptides (29, 30) .
Because MAGE-1 belongs to a family of several highly
related genes, it was of interest to compare these genes in
the region that is homologous to the region of MAGE-1 that
codes for the MZ2-E peptide. As shown in Fig. 4, other MAGE
genes code for peptides that are not identical to the MZ2-E
3
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Figure 3 . (A) Lysisby anti-MZ2-E
CTL of mouse cells expressing
HLA.Al in the presence of the
MZ2-E peptide. P1.HTR mouse
cells expressing HLA-A1 were ob-
tained by transfection . These
P1.HTR.A1 cells, as well as control
cells P1.HTR and MZ2-MEL.2.2
(E - ), were chromium labeled and
incubated with anti-MZ2-E CTL
82/30 at various E/T ratios in the
presence of the MZ2-E nonapeptide
EADPTGHSY Chromium release
was measured after 4 h . (B) . Lysis
by anti-MZ2-E CTL ofmouse cells
transfected with HLA-A1 and
MAGE-1.
P1.HTR P1 .HTR.A1 MZ2-MEL .2 .2
(E- )
MZ2-MEL
(E} )
P1,AI .MAGE-1
-0
O-O-O-O 0-
2IAGE 1 E A D P T G H S Y
MAGE 2 E V V P I S H L Y
MAGE 21 E V V R I G H L Y
MAGE 3 E V D P I G H L Y
MAGE 4 E V D P A S N T Y
MAGE 41 E V D P T S N T Y
MAGE 5 E A D P T S N T Y
MAGE 51 E A D P T S N T Y
MAGE 6 E V D P I G H V Y
peptide. It is therefore likely that none of these genes codes
for the antigen recognized by theCTLdirected against MZ2-E.
In agreement with this, we have observed that HLA-Al cells
expressing one or several of the genes MAGE-2, MAGE-3,
and MAGE-4 are not recognized by the anti-E CTL. The
conservation of the terminal Glu and Tyr in all the peptides
displayed in Fig. 4 is worth noting. Preliminary experiments
carried out with some of these peptides containing terminal
Glu and Tyr residues failed to compete with the MZ2-E pep-
tide for sensitization to the anti-E CTL. This suggests that
binding to HLAAl requires more than these two constant
residues.
The availability of a gene encoding a tumor antigen rec-
ognized by CTL provides the possibility of selecting for im-
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